Objective: To explore the clinical value of tumor markers, serum inflammatory factors and costimulatory molecule B7-H6 expression in cervical. Methods: A retrospective collection of 80 patients with cervical cancer lesions hospitalized in Shijiazhuang Maternity and Child Healthcare Hospital from June 2019 to September 2020. According to the pathologicalresults, they were divided into 40 cases of cervical cancer group and 40 cases of cervical benign group. Another 40 cases who were taking normal physical examination during the same period were selected as the control group. We compared the levels of tumor markers [squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), sugar chain antigen 125 (CA125)], serum inflammatory factor [interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ)] levels and the expression of costimulatory molecule B7-H6 among the three groups. Results: Compared with the control group, the expression levels of SCCA, CEA, CA125, TNF-α, B7-H6 in the cervical cancer group and the cervical benign group were significantly increased; and the levels of SCCA, CEA, CA125, TNF-α, B7-H6 in cervical cancer group were significantly higher than those of the cervical benign group; all the differences were statistically significant (P<0.05). Compared with the control group, the expression levels of IL-2 and IFN-γ in the cervical cancer group and the benign cervical group were significantly lower; and the expression levels of IL-2 and IFN-γ in the cervical cancer group were significantly lower than those in the benign cervical group; and all the differences were statistically significant (all P<0.05). Conclusion: The expression levels of tumor markers (SCCA, CEA, CA125), serum inflammatory factors (IL-2, IFN-γ, TNF-α) and costimulatory molecule B7-H6 are closely related to the development of cervical cancer and can be important auxiliary indexes for clinical diagnosis.
 BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
 周晖,王东雁,罗铭,等.《FIGO 2018妇癌报告》—子宫颈癌指南解读[J].中国实用妇科与产科杂志,2019,35(1):95-103.
 PIMPLE S,MISHRA G,SHASTRI S.Global strategies for cervical cancer prevention[J].Curr Opin Obstet Gynecol,2016,28(1):4-10.
 GUTIERREZ-SILERIO G Y,FRANCO-TOPETE R A,HARAMATI J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):1-9.
 周晖,白守民,林仲秋.《2018 NCCN宫颈癌临床实践指南(第一版)》解读[J].中国实用妇科与产科杂志,2017,33(12):1255-1261.
 PATEL S,CHIPLUNKAR S.Host immune responses to cervical cancer[J].Curr Opin Obstet Gynecol,2009,21(1):54-59.
 VITKAUSKAITE A,URBONIENE D,CELIESIUTE J,et al.Circulating inflammatory markers in cervical cancer patients and healthy controls[J].J Immunotoxicol,2020,17(1):105-109.
 PARADKAR P H,JOSHI J V,MERTIA P N,et al.Role of cytokines in genesis,progression and prognosis of cervical cancer[J].Asian Pac J Cancer Prev,2014,15(9):3851-3864.
 TODORIC J,ANTONUCCI L,KARIN M.Targeting inflammation in cancer prevention and therapy[J].Cancer Prev Res,2016,9(12):895-905.
 ARTURO V M,ADRIANA G H,CARMEN L M,et al.Pleiotropic effects of IL-2 on cancer:its role in cervical cancer[J].Mediators Inflamm,2016,2016:2849523.
 KOTOWICZ B,FUKSIEWICZ M,JONSKA-GMYREK J,et al.The assessment of the prognostic value of tumor markers and cytokines as SCCAg,CYFRA 21.1,IL-6,VEGF and sTNF receptors in patients with squamous cell cervical cancer,particularly with early stage of the disease[J].Tumour Biol,2016,37(1):1271-1278.
 ZHAO W,YU H,HAN Z,et al.Clinical significance of joint detection of serum CEA,SCCA,and bFGF in the diagnosis of lung cancer[J].Int J Clin Exp Pathol,2015,8(8):9506-9511.
 ZAMANI N,GILANI M M,ZAMANI F,et al.Utility of pelvic MRI and tumor markers HE4 and CA125 to predict depth of myometrial invasion and cervical involvement in endometrial cancer[J].J Family Reprod Health,2015,9(4):177-183.
 SUN X,ZHAO J,MA L,et al.B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells[J].Invest New Drugs,2021,39(1):24-33.
 BANU N,RIERA-LEAL A,HARAMATI J,et al.B7-H6,an immunoligand for the natural killer cell activating receptor NKp30,reveals inhibitory effects on cell proliferation and migration,but not apoptosis,in cervical cancer derived-cell lines[J].BMC Cancer,2020,20(1):1083.
 GUTIERREZ-SILERIO G Y,FRANCO-TOPETE R A,HARAMATI J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):9.